These results suggest that RhoA/RhoC and YAP could become promising targets for molecular therapy, and rhosin may provide an extremely useful pharmacotherapeutic approach in the treatment of melanoma and breast cancer patients. This evidence concerns the gene RHOC and breast carcinoma.